Literature DB >> 27089522

Combining clinical variables to optimize prediction of antidepressant treatment outcomes.

Raquel Iniesta1, Karim Malki2, Wolfgang Maier3, Marcella Rietschel4, Ole Mors5, Joanna Hauser6, Neven Henigsberg7, Mojca Zvezdana Dernovsek8, Daniel Souery9, Daniel Stahl10, Richard Dobson2, Katherine J Aitchison11, Anne Farmer2, Cathryn M Lewis2, Peter McGuffin2, Rudolf Uher12.   

Abstract

The outcome of treatment with antidepressants varies markedly across people with the same diagnosis. A clinically significant prediction of outcomes could spare the frustration of trial and error approach and improve the outcomes of major depressive disorder through individualized treatment selection. It is likely that a combination of multiple predictors is needed to achieve such prediction. We used elastic net regularized regression to optimize prediction of symptom improvement and remission during treatment with escitalopram or nortriptyline and to identify contributing predictors from a range of demographic and clinical variables in 793 adults with major depressive disorder. A combination of demographic and clinical variables, with strong contributions from symptoms of depressed mood, reduced interest, decreased activity, indecisiveness, pessimism and anxiety significantly predicted treatment outcomes, explaining 5-10% of variance in symptom improvement with escitalopram. Similar combinations of variables predicted remission with area under the curve 0.72, explaining approximately 15% of variance (pseudo R(2)) in who achieves remission, with strong contributions from body mass index, appetite, interest-activity symptom dimension and anxious-somatizing depression subtype. Escitalopram-specific outcome prediction was more accurate than generic outcome prediction, and reached effect sizes that were near or above a previously established benchmark for clinical significance. Outcome prediction on the nortriptyline arm did not significantly differ from chance. These results suggest that easily obtained demographic and clinical variables can predict therapeutic response to escitalopram with clinically meaningful accuracy, suggesting a potential for individualized prescription of this antidepressant drug.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antidepressant; Depression; Machine learning; Outcome; Prediction; Statistical learning

Mesh:

Substances:

Year:  2016        PMID: 27089522     DOI: 10.1016/j.jpsychires.2016.03.016

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  36 in total

1.  Duloxetine effects on striatal resting-state functional connectivity in patients with major depressive disorder.

Authors:  Li Wang; Jing An; Hong-Mei Gao; Ping Zhang; Chao Chen; Ke Li; Philip B Mitchell; Tian-Mei Si
Journal:  Hum Brain Mapp       Date:  2019-05-08       Impact factor: 5.038

2.  Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder.

Authors:  Arjun Athreya; Ravishankar Iyer; Drew Neavin; Liewei Wang; Richard Weinshilboum; Rima Kaddurah-Daouk; John Rush; Mark Frye; William Bobo
Journal:  IEEE Comput Intell Mag       Date:  2018-07-20       Impact factor: 11.356

3.  Recent Findings of the Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder: Do We Now Know What to Prescribe?

Authors:  Matthew V Rudorfer
Journal:  CNS Drugs       Date:  2018-09       Impact factor: 5.749

Review 4.  The Heterogeneity Problem: Approaches to Identify Psychiatric Subtypes.

Authors:  Eric Feczko; Oscar Miranda-Dominguez; Mollie Marr; Alice M Graham; Joel T Nigg; Damien A Fair
Journal:  Trends Cogn Sci       Date:  2019-05-29       Impact factor: 20.229

Review 5.  Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Bernhard T Baune
Journal:  EPMA J       Date:  2017-09-05       Impact factor: 6.543

Review 6.  Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.

Authors:  Abdullah Al Maruf; Mikayla Fan; Paul D Arnold; Daniel J Müller; Katherine J Aitchison; Chad A Bousman
Journal:  Can J Psychiatry       Date:  2020-02-17       Impact factor: 4.356

7.  Predicting treatment outcome in depression: an introduction into current concepts and challenges.

Authors:  Nicolas Rost; Elisabeth B Binder; Tanja M Brückl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-19       Impact factor: 5.270

8.  Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.

Authors:  Karim Malki; Maria Grazia Tosto; Héctor Mouriño-Talín; Sabela Rodríguez-Lorenzo; Oliver Pain; Irfan Jumhaboy; Tina Liu; Panos Parpas; Stuart Newman; Artem Malykh; Lucia Carboni; Rudolf Uher; Peter McGuffin; Leonard C Schalkwyk; Kevin Bryson; Mark Herbster
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-10-01       Impact factor: 3.568

9.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

10.  AI in patient flow: applications of artificial intelligence to improve patient flow in NHS acute mental health inpatient units.

Authors:  Fatema Mustansir Dawoodbhoy; Jack Delaney; Paulina Cecula; Jiakun Yu; Iain Peacock; Joseph Tan; Benita Cox
Journal:  Heliyon       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.